357 related articles for article (PubMed ID: 17891164)
21. Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.
Lever IJ; Pheby TM; Rice AS
Br J Pharmacol; 2007 May; 151(2):292-302. PubMed ID: 17375083
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit.
Ganon-Elazar E; Akirav I
Psychoneuroendocrinology; 2013 Sep; 38(9):1675-87. PubMed ID: 23433741
[TBL] [Abstract][Full Text] [Related]
23. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice.
Martellotta MC; Cossu G; Fattore L; Gessa GL; Fratta W
Neuroscience; 1998 Jul; 85(2):327-30. PubMed ID: 9622233
[TBL] [Abstract][Full Text] [Related]
24. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
25. The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward.
Flores Á; Maldonado R; Berrendero F
Biol Psychiatry; 2014 Mar; 75(6):499-507. PubMed ID: 23896204
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.
Burgos E; Gómez-Nicola D; Pascual D; Martín MI; Nieto-Sampedro M; Goicoechea C
Eur J Pharmacol; 2012 May; 682(1-3):62-72. PubMed ID: 22374260
[TBL] [Abstract][Full Text] [Related]
27. Retention and extinction of delay eyeblink conditioning are modulated by central cannabinoids.
Steinmetz AB; Freeman JH
Learn Mem; 2011 Oct; 18(10):634-8. PubMed ID: 21940395
[TBL] [Abstract][Full Text] [Related]
28. Adolescent cannabinoid exposure induces irritability-like behavior and cocaine cross-sensitization without affecting the escalation of cocaine self-administration in adulthood.
Kononoff J; Melas PA; Kallupi M; de Guglielmo G; Kimbrough A; Scherma M; Fadda P; Kandel DB; Kandel ER; George O
Sci Rep; 2018 Sep; 8(1):13893. PubMed ID: 30224774
[TBL] [Abstract][Full Text] [Related]
29. Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.
Radziszewska E; Bojanowska E
Med Sci Monit Basic Res; 2013 Jan; 19():6-11. PubMed ID: 23291632
[TBL] [Abstract][Full Text] [Related]
30. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.
Cui JH; Kim WM; Lee HG; Kim YO; Kim CM; Yoon MH
Neurosci Lett; 2011 Apr; 493(3):67-71. PubMed ID: 21195743
[TBL] [Abstract][Full Text] [Related]
31. WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation.
Vlachou S; Nomikos GG; Panagis G
Behav Brain Res; 2003 May; 141(2):215-22. PubMed ID: 12742258
[TBL] [Abstract][Full Text] [Related]
32. Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.
Gomez DM; Everett TJ; Hamilton LR; Ranganath A; Cheer JF; Oleson EB
Neuropharmacology; 2021 Jan; 182():108374. PubMed ID: 33115642
[TBL] [Abstract][Full Text] [Related]
33. Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats.
Drews E; Schneider M; Koch M
Pharmacol Biochem Behav; 2005 Jan; 80(1):145-50. PubMed ID: 15652390
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat.
Hohmann AG; Tsou K; Walker JM
J Neurophysiol; 1999 Feb; 81(2):575-83. PubMed ID: 10036261
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test.
Yoon MH; Choi JI
Anesthesiology; 2003 Sep; 99(3):701-7. PubMed ID: 12960556
[TBL] [Abstract][Full Text] [Related]
36. WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors.
Pamplona FA; Takahashi RN
Neurosci Lett; 2006 Apr 10-17; 397(1-2):88-92. PubMed ID: 16406322
[TBL] [Abstract][Full Text] [Related]
37. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.
De Vry J; Jentzsch KR; Kuhl E; Eckel G
Behav Pharmacol; 2004 Feb; 15(1):1-12. PubMed ID: 15075621
[TBL] [Abstract][Full Text] [Related]
38. Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy.
Bujalska M
Pharmacology; 2008; 82(3):193-200. PubMed ID: 18810243
[TBL] [Abstract][Full Text] [Related]
39. Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.
Spano MS; Fattore L; Cadeddu F; Fratta W; Fadda P
Psychopharmacology (Berl); 2013 Feb; 225(3):531-42. PubMed ID: 22903392
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study.
Gallo A; Bouchard C; Fortier E; Ducrot C; Rompré PP
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1534-45. PubMed ID: 25092427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
